Japanese pharmaceutical company
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?: The first drug shown to slow Alzheimer’s hit the U.S. market over a year ago ...
apnews.com/article/alzheimer-leqembi-slow-start-f9022b85b16cc6de4491594ce875657b
AstraZeneca’s add-on treatment for rare blood disease gets USFDA nod: In 2021, AstraZeneca gained the drug in its acquisition of Alexion for $39 billion. In 2019 ...
financialexpress.com/healthcare/pharma-healthcare/astrazenecas-add-on-treatment-for-rare-blood-disease-gets-usfda-nod/3444136/
EU regulator delays decision on Eisai-Biogen Alzheimer's drug: The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's ...
reuters.com/business/healthcare-pharmaceuticals/eu-drug-regulator-does-not-refer-eisai-biogen-alzheimers-drug-meeting-notes-2024-03-22/
Eisai: All About Lenvima And Leqembi: Lenvima and Leqembi should continue to deliver, and Eisai (ESALF) is well positioned with its strategic partnerships ...
seekingalpha.com/article/4678737-eisai-all-about-lenvima-and-leqembi
Paid articlePaid
Japan's Eisai to invest in U.S. Alzheimer's blood testing firm C2N: TOKYO -- Japanese drugmaker Eisai said Wednesday it will invest up to $15 million in C2N ...
asia.nikkei.com/Business/Pharmaceuticals/Japan-s-Eisai-to-invest-in-U.S.-Alzheimer-s-blood-testing-firm-C2N2
Ground-breaking drug to be given to 1,500 Alzheimer’s patients in China: Leqembi works by removing a toxic protein called beta amyloid from the brain.
straitstimes.com/asia/eisai-expects-1500-alzheimers-patients-in-china-launch-sees-huge-growth
US FDA delays decision on Lilly's Alzheimer's drug: Eli Lilly released clinical trial data last year that it says showed the treatment to be safe and effective ...
freemalaysiatoday.com/category/business/2024/03/08/us-fda-delays-decision-on-lillys-alzheimers-drug/
Exclusive: Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge’ growth
reuters.com/business/healthcare-pharmaceuticals/eisai-expects-1500-alzheimers-patients-china-launch-sees-huge-growth-2024-02-04/
US delays approval of Eli Lilly Alzheimer's treatment: Lilly said no date has been set yet for the advisory committee meeting to discuss the medicine ...
irishexaminer.com/business/companies/arid-41348894.html
Eisai sees 'huge' growth potential for Alzheimer's drug in China: The Japanese pharmaceutical firm aims to roll out its groundbreaking Alzheimer’s drug Leqembi ...
japantimes.co.jp/business/2024/02/05/companies/eisai-alzheimers-drug-china/
Biogen to shut down controversial Alzheimer's drug Aduhelm: Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential ...
apnews.com/article/biogen-alzheimer-aduhelm-dfb364a61e4e77da27fc055e826b9a49
Quick Glance: Biogen Halts Production of Alzheimer’s Drug Aduhelm
- Biogen halts production of Alzheimer’s drug Aduhelm, focusing on Leqembi and developing other treatments for the disease.
- The decision to end development of the drug was not related to safety or efficacy concerns.
- The US Food and Drug Administration will end its study needed for full approval of the drug.
- The US Congress criticized the collaboration between Biogen and the FDA, concluding that the high price of the drug was unjustified.
Biogen launch of Leqembi Alzheimer’s drug off to slow start: Only about 2,000 patients are taking the medicine nationwide, but Biogen’s chief executive ...
bostonglobe.com/2024/02/13/business/biogen-leqembi-alzheimers-eisai-christopher-a-viebacher/
China approves Alzheimer's treatment Leqembi by Eisai and Biogen: Eisai (4523.T) and Biogen (BIIB.O) said on Tuesday that their Alzheimer's treatment Leqembi had ...
reuters.com/business/healthcare-pharmaceuticals/china-approves-alzheimers-treatment-leqembi-by-eisai-biogen-2024-01-09/
China approves Alzheimer's treatment Leqembi by Eisai and Biogen: Eisai (4523.T) and Biogen (BIIB.O) said on Tuesday that their Alzheimer's treatment Leqembi had ...
reuters.com/business/healthcare-pharmaceuticals/china-approves-alzheimers-treatment-leqembi-by-eisai-biogen-2024-01-09/
Quick Glance: VW utilizing ChatGPT for driver conversations by mid-year
- Volkswagen integrating ChatGPT to enable driver conversations by mid-year.
- First vehicles with ChatGPT available in North America and Europe from early second quarter.
- AI system capable of recognizing and responding to various demands, such as temperature adjustments and displaying nearby restaurants.
Stock Of The Day Lilly Is In A Buy Zone. And It's Not Related To Obesity.: Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are rallying on ...
investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-rallies-into-buy-zone-on-surprising-results-in-treating-deafness/
Eisai seeks expanded use of Alzheimer's drug for prevention: TOKYO -- Japanese drugmaker Eisai will apply for regulatory approval in the U.S ...
asia.nikkei.com/Business/Pharmaceuticals/Eisai-seeks-expanded-use-of-Alzheimer-s-drug-for-prevention
New Alzheimer's drug to be covered by health insurance in Japan: The drug, to be launched Dec. 20, will cost around ¥2.98 million per year in Japan but patients ...
japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/
Washington U. creates drug research company, backed by $130 million from New York firm
stltoday.com/news/local/business/washington-u-creates-drug-research-company-backed-by-130-million-from-new-york-firm/article_e172bd6a-b187-11ee-b1dd-bff3937cfd2d.html
Eisai-Biogen Alzheimer's therapy to cost ¥2.98 mil per year: A single course of treatment with an Alzheimer's drug developed by Japanese company Eisai ...
japantoday.com/category/features/health/update1-eisai-biogen-alzheimer&
Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial: Merck (MRK.N) said on Friday a combination therapy being developed with partner ...
reuters.com/business/healthcare-pharmaceuticals/merck-eisais-cancer-therapy-combo-fails-late-stage-study-2023-12-08/
Researchers return to Alzheimer's vaccines, buoyed by recent drug success: Breakthrough Alzheimer’s treatments that remove toxic proteins from the brain have ...
reuters.com/business/healthcare-pharmaceuticals/researchers-return-alzheimers-vaccines-buoyed-by-recent-drug-success-2023-11-20/
Eisai Shares Drop on Outlook Even With Alzheimer’s Drug Sales: Eisai Co. is aiming for ¥10 billion ($66.5 million) in sales of its Alzheimer’s drug Leqembi for ...
bloomberg.com/news/articles/2023-11-07/eisai-shares-drop-on-outlook-even-with-alzheimer-s-drug-sales
Eisai Alzheimer Drug Shows Promise in Injectable-At-Home Version: An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes ...
bloomberg.com/news/articles/2023-10-25/eisai-alzheimer-drug-shows-promise-in-injectable-at-home-version
Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests
cnn.com/2023/10/25/health/alzheimers-drug-leqembi-could-be-given-as-shots-rather-than-iv-infusion-study-suggests/
Anti-fungal agent from Eisai: medicine for the world's poorest patients: The Japanese pharmaceutical company Eisai is testing its therapy not only against nail ...
tagesanzeiger.ch/anti-pilz-mittel-von-eisai-medikament-fuer-die-aermsten-kranken-der-welt-450233314151
Alzheimer’s: Biogen and Eli Lilly present clinical treatment data: Cambridge-based Biogen is vying with the pharmaceutical giant Eli Lilly for leadership in the ...
bostonglobe.com/2023/10/25/business/biogen-eli-lilly-alzheimers-clinical/
Why Diagnosing Alzheimer’s Early Is So Important: New data from Eli Lilly and Eisai show that their Alzheimer's drugs are more effective when started earlier in ...
time.com/6328482/alzheimers-lecanemab-early-diagnosis/
Blood tests needed for widespread Alzheimer's diagnosis on the way: Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and ...
reuters.com/business/healthcare-pharmaceuticals/blood-tests-needed-widespread-alzheimers-diagnosis-way-2023-10-11/
Down syndrome families' fight for access to Alzheimer’s trials, treatments: When Lianor da Cunha Hillerstrom of Lexington, Massachusetts, learned her now ...
reuters.com/business/healthcare-pharmaceuticals/down-syndrome-families-fight-access-alzheimers-trials-treatments-2023-10-10/
Eisai’s Alzheimer’s Drug Wins Approval in Japan, Following US: Eisai Co.’s breakthrough Alzheimer’s disease drug won clearance from Japanese regulators after the ...
bloomberg.com/news/articles/2023-09-25/eisai-s-alzheimer-s-drug-wins-approval-in-japan-following-us
UK biotech group raises £48mn for Alzheimer’s research: AstronauTx’s financing is step towards helping millions of people suffering from disease
ft.com/content/c8cc98a0-ef9e-4b44-a3b2-f18a9ed487f4
Paid articlePaid Merck, Eisai's combination therapy fails in lung cancer studies: Drugmakers Merck (MRK.N) and Eisai (4523.T) said on Friday a combination of their cancer ...
reuters.com/business/healthcare-pharmaceuticals/drugmaker-merck-says-keytruda-combination-fails-lung-cancer-trial-2023-09-22/
With Alzeimer’s drug Leqembi getting full FDA approval, Medicaire to start paying for it
miamiherald.com/living/health-fitness/healthcare/article279623819.html
Japan set to approve Alzheimer's drug Leqembi as soon as Monday: TOKYO -- Japan's health ministry is preparing to formally approve as early as Monday the ...
asia.nikkei.com/Business/Pharmaceuticals/Japan-set-to-approve-Alzheimer-s-drug-Leqembi-as-soon-as-Monday
Paid articlePaid Merck, Eisai discontinue late-stage study for combo cancer therapy: Merck & Co (MRK.N) and partner Eisai (4523.T) said on Friday they will shut down a late-stage ...
reuters.com/business/healthcare-pharmaceuticals/merck-eisai-discontinue-late-stage-study-cancer-therapy-2023-08-25/
Eisai CEO Hails Significant Step in Fight Against Dementia: Eisai Co. CEO Haruo Naito hailed the significant step in the battle against dementia after the ...
japannews.yomiuri.co.jp/business/companies/20230926-139246/
Japan panel OKs Alzheimer's drug, paves way for formal approval - The Mainichi: TOKYO (Kyodo) -- A Japanese health ministry panel on Monday gave the green light ...
mainichi.jp/english/articles/20230821/p2g/00m/0sc/044000c
Eisai Azheimer’s Drug Set to Win Japanese Approval, Following US: Eisai Co.’s breakthrough Alzheimer’s disease drug is poised to gain the backing of Japanese ...
bloomberg.com/news/articles/2023-08-21/eisai-azheimer-s-drug-set-to-win-japanese-approval-following-us
Major US health systems expect to offer Alzheimer's drug Leqembi in a few months: Five major U.S. health systems said they would offer Eisai and Biogen's ...
reuters.com/business/healthcare-pharmaceuticals/major-us-health-systems-expect-offer-alzheimers-drug-leqembi-few-months-2023-08-07/
Quick Glance: Major US health systems to offer Alzheimer's drug Leqembi in a few months
- Five major US health systems will offer the promising new Alzheimer's drug Leqembi.
- The drug is expected to be rolled out in the next few months.
- Neurologists at renowned clinics like Mayo Clinic, Northwestern Memorial, and Cedars-Sinai also plan to introduce the drug.
- Medicare is expected to reimburse the drug.
Quest Diagnostics launches Alzheimer's blood test for consumers: Quest Diagnostics (DGX.N) on Monday launched the first direct-to-consumer blood test to detect ...
reuters.com/business/healthcare-pharmaceuticals/quest-diagnostics-launches-alzheimers-blood-test-consumers-2023-07-31/
Quick Glance: Quest Diagnostics introduces Alzheimer's blood test for consumers
- Quest Diagnostics has launched the first direct-to-consumer blood test to detect abnormal levels of the Alzheimer's protein beta amyloid.
- Priced at $399, the AD-Detect test utilizes the same technology as a blood test previously released by the company for use by doctors in early 2022.
- The announcement follows the recent full U.S. regulatory approval of Leqembi, a drug developed by Eisai and Biogen, which removes amyloid from the brain and has demonstrated the ability to slow the progression of Alzheimer's in early-stage patients.
- Users are required to make payment for the test on Quest's website.
Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks: Groundbreaking treatments for Alzheimer's disease that work by removing a toxic ...
reuters.com/business/healthcare-pharmaceuticals/promising-new-alzheimers-drugs-may-benefit-whites-more-than-blacks-2023-07-31/
Eisai Eyes Japan, China for Alzheimer’s Drug After US Approval: Eisai Co.’s new global Alzheimer’s officer Keisuke Naito is shifting the focus of the program to ...
bloomberg.com/news/articles/2023-08-02/eisai-eyes-japan-china-for-alzheimer-s-drug-after-us-approval
Biogen announces job cuts, turns focus to Alzheimer's drug launch: Biogen Inc (BIIB.O) said on Tuesday it expects to slash about 1,000 jobs ...
reuters.com/business/healthcare-pharmaceuticals/biogen-cut-1000-jobs-save-costs-alzheimers-drug-launch-gathers-pace-2023-07-25/
New Drug for Dementia: Put System in Place to Move toward Practical Application: A new drug for dementia is likely to be put to practical use by the end of this ...
japannews.yomiuri.co.jp/editorial/yomiuri-editorial/20230823-131547/
FDA Makes Alzheimer’s Drug Leqembi Widely Accessible: The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks ...
nytimes.com/2023/07/06/health/alzheimers-leqembi-medicare.html
Quick Glance: FDA Expands Access to Alzheimer's Drug Leqembi
- Medicare will cover most of the high cost.
- Alzheimer's experts say the evidence supporting Leqembi is much clearer.
- The decision to grant full approval to Leqembi means that Medicare will cover it for eligible patients.
- However, some patients may be unable to afford the 20 percent that Medicare does not cover, amounting to about $6,600 per year.
Alzheimer's drug firm Eisai secures approval in Japan: Eisai is also seeking approval of the medicine in other markets, including Europe and China
irishexaminer.com/business/companies/arid-41209423.html
Eisai to enable Alzheimer's drug to be injected at home: TOKYO -- Japanese pharmaceutical company Eisai plans to further develop lecanemab ...
asia.nikkei.com/Business/Pharmaceuticals/Eisai-to-enable-Alzheimer-s-drug-to-be-injected-at-home
Eisai to enable Alzheimer's drug Leqembi to be injected at home: TOKYO -- Japanese pharmaceutical company Eisai plans to further develop lecanemab ...
asia.nikkei.com/Business/Pharmaceuticals/Eisai-to-enable-Alzheimer-s-drug-Leqembi-to-be-injected-at-home
Eisai's Alzheimer's drug takes step toward widespread use: TOKYO -- With the U.S. regulators formally approving Alzheimer's disease treatment lecanemab ...
asia.nikkei.com/Business/Pharmaceuticals/Eisai-s-Alzheimer-s-drug-takes-step-toward-widespread-use
New Alzheimer’s Drug Is First to Show It Slows Disease. But It’s Facing a Rocky Rollout
bloomberg.com/news/articles/2023-07-13/leqembi-eisai-s-alzheimer-s-drug-faces-bumpy-rollout-after-us-approval
8 Undervalued Quality Healthcare Stocks: These wide-moat healthcare stocks are trading below their fair value estimates.
morningstar.com/stocks/8-undervalued-quality-healthcare-stocks
The first drug that slows Alzheimer's has finally received FDA approval: Japanese drugmaker Eisai and US-based Biogen have received FDA approval for Leqembi ...
engadget.com/the-first-drug-that-slows-alzheimers-has-finally-received-fda-approval-165058452.html
Expectations grow for Alzheimer's drug in Japan, but hurdles remain: Lecanemab could be approved in the country as early as fall, but more specialist ...
japantimes.co.jp/news/2023/07/04/national/science-health/lecanemab-japan-approval-expectations/
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
cnbc.com/2023/07/08/leqembi-and-medicare-what-patients-and-doctors-should-know.html
Thousands of unauthorized vapes are pouring into the US despite the FDA crackdown on fruity flavors
apnews.com/article/fda-vapes-vaping-elf-bar-juul-80b2680a874d89b8d651c5e909e39e8f
Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program: Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung ...
bloomberg.com/news/articles/2023-07-11/eisai-appoints-ceo-s-son-to-lead-global-alzheimer-drug-program
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
cnbc.com/2023/07/17/alzheimers-eli-lilly-expects-fda-decision-on-donanemab-by-year-end.html
US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi: A panel of expert advisers on Friday unanimously agreed that a late-stage trial of Eisai ...
reuters.com/business/healthcare-pharmaceuticals/fda-panel-debate-us-approval-alzheimers-drug-eisai-biogen-2023-06-09/
New Alzheimer’s drug is first to show it slows disease. But it’s facing a rocky rollout
mercurynews.com/2023/07/18/new-alzheimers-drug-is-first-to-show-it-slows-disease-but-its-facing-a-rocky-rollout/
European Alzheimer's experts unconvinced by new Eisai, Biogen drug: Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai (4523 ...
reuters.com/business/healthcare-pharmaceuticals/european-alzheimers-experts-unconvinced-by-new-eisai-biogen-drug-2023-06-13/
Lilly (LLY) Applies for Alzheimer’s Drug’s US Approval After Trial Success: Eli Lilly & Co. said it applied for full US approval of its Alzheimer’s disease ...
bloomberg.com/news/articles/2023-07-17/lilly-lly-applies-for-alzheimer-s-drug-s-us-approval-after-trial-success
Using AI and genetics to find treatments for dog and human cancer: A study shows that dogs and humans share similar cancer genes. One company is aiming to ...
businessinsider.com/using-ai-genetics-find-treatments-dog-human-cancer-2023-7
Paid articlePaid
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it
gazette.com/ap/alzheimer-s-drug-leqembi-has-full-fda-approval-now-and-that-means-medicare-will-pay/article_ad8876b4-b794-5159-b45c-3aec20d27f0f.html
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its ... Show more reut.rs/3Nsb4VM
Alzheimer's drug trials raise questions about patient risks, ability to consent: A gold rush in Alzheimer's pharmaceutical research raises questions about ...
latimes.com/business/story/2023-07-10/californians-recruited-alzheimers-drug-trials-consent-risks
US FDA has approved new Alzheimer's medicine
Drug Leqembi has been developed jointly by US' Biogen & Japan's Eisai
Watch more: wionews.com/videos
Eli Lilly surpasses UnitedHealth as world’s biggest health-care firm: Eli Lilly & Co became the world’s biggest health-care company by market value ...
deccanherald.com/business/business-news/eli-lilly-surpasses-unitedhealth-as-world-s-biggest-health-care-firm-1234368.html
Eisai, Biogen Get FDA Advisers’ Support for Alzheimer Drug’s Full Approval: Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from ...
bloomberg.com/news/articles/2023-06-09/first-disease-slowing-alzheimer-s-drug-clears-hurdle-for-full-fda-approval
Eisai, Biogen Clinch FDA Advisers’ Support for Alzheimer’s Drug: Eisai Co.’s Alzheimer’s disease drug developed with Biogen Inc. gained support from advisers to ...
bloomberg.com/news/articles/2023-06-12/eisai-biogen-clinch-fda-advisers-support-for-alzheimer-s-drug
Ransomware scum hit Japanese pharma giant Eisai Group: Some servers encrypted in weekend attack, but product supply not affected
theregister.com/2023/06/09/eisai_group_hit_by_ransomware/
Japanese pharma giant Eisai discloses ransomware attack: Pharmaceutical company Eisai has disclosed it suffered a ransomware incident that impacted its ...
bleepingcomputer.com/news/security/japanese-pharma-giant-eisai-discloses-ransomware-attack/
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
cnbc.com/2023/06/07/sanders-condemns-alzheimers-treatment-price-calls-for-hhs-action.html
Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds
reuters.com/business/healthcare-pharmaceuticals/eisai-biogen-alzheimers-drug-leqembi-would-cost-us-medicare-up-5-bln-year-study-2023-05-11/
Alzheimer’s Drugs Are Arriving, But They Won’t Be Risk Free: Hi, it’s Bob in New York. New Alzheimer’s drugs from Eisai and Eli Lilly can slow the disease ...
bloomberg.com/news/newsletters/2023-05-23/alzheimer-s-drugs-are-arriving-but-they-won-t-be-risk-free
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
cnbc.com/2023/05/12/alzheimers-disease-leqembi-could-cost-medicare-5-billion-per-year.html
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics